Synendos Therapeutics takes in Series A

Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing.

12 November 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles